Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells
- PMID: 24883377
- PMCID: PMC4032698
- DOI: 10.1155/2014/282147
Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells
Abstract
Early and late endocrine disorders are among the most common complications in survivors after hematopoietic allogeneic- (allo-) and autologous- (auto-) stem cell transplant (HSCT). This review summarizes main endocrine disorders reported in literature and observed in our center as consequence of auto- and allo-HSCT and outlines current options for their management. Gonadal impairment has been found early in approximately two-thirds of auto- and allo-HSCT patients: 90-99% of women and 60-90% of men. Dysfunctions of the hypothalamus-pituitary-growth hormone/insulin growth factor-I axis, hypothalamus-pituitary-thyroid axis, and hypothalamus-pituitary-adrenal axis were documented as later complicances, occurring in about 10, 30, and 40-50% of transplanted patients, respectively. Moreover, overt or subclinical thyroid complications (including persistent low-T3 syndrome, chronic thyroiditis, subclinical hypo- or hyperthyroidism, and thyroid carcinoma), gonadal failure, and adrenal insufficiency may persist many years after HSCT. Our analysis further provides evidence that main recognized risk factors for endocrine complications after HSCT are the underlying disease, previous pretransplant therapies, the age at HSCT, gender, total body irradiation, posttransplant derangement of immune system, and in the allogeneic setting, the presence of graft-versus-host disease requiring prolonged steroid treatment. Early identification of endocrine complications can greatly improve the quality of life of long-term survivors after HSCT.
Figures

Similar articles
-
[Evaluation of selected endocrine complications in patients treated with auto- and allo-haematopoietic stem cell transplantation].Med Wieku Rozwoj. 2008 Jul-Sep;12(3):761-6. Med Wieku Rozwoj. 2008. PMID: 19305027 Polish.
-
Clinical Impact of Pretransplant Multidrug-Resistant Gram-Negative Colonization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant. 2018 Jul;24(7):1476-1482. doi: 10.1016/j.bbmt.2018.02.021. Epub 2018 Mar 2. Biol Blood Marrow Transplant. 2018. PMID: 29501780
-
High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases.Cancer. 2002 Sep 1;95(5):1076-84. doi: 10.1002/cncr.10773. Cancer. 2002. PMID: 12209694
-
Endocrine late effects after hematopoietic stem cell transplantation.Oncol Res. 2010;18(11-12):607-15. doi: 10.3727/096504010x12777678141707. Oncol Res. 2010. PMID: 20939437 Review.
-
A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature.Front Immunol. 2020 May 5;11:668. doi: 10.3389/fimmu.2020.00668. eCollection 2020. Front Immunol. 2020. PMID: 32431694 Free PMC article. Review.
Cited by
-
[Fertility analyses of patients with hematologic diseases after allogeneic hematopoietic stem cell transplantation].Zhonghua Xue Ye Xue Za Zhi. 2019 Jul 14;40(7):605-607. doi: 10.3760/cma.j.issn.0253-2727.2019.07.014. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 32397027 Free PMC article. Chinese. No abstract available.
-
Assessing Cachexia Acutely after Autologous Stem Cell Transplant.Cancers (Basel). 2019 Sep 4;11(9):1300. doi: 10.3390/cancers11091300. Cancers (Basel). 2019. PMID: 31487803 Free PMC article.
-
Prevalence of Ototoxicity Following Hematopoietic Stem Cell Transplantation in Pediatric Patients.Biol Blood Marrow Transplant. 2020 Jan;26(1):107-113. doi: 10.1016/j.bbmt.2019.08.028. Epub 2019 Sep 5. Biol Blood Marrow Transplant. 2020. PMID: 31494228 Free PMC article. Clinical Trial.
-
Anti-Muellerian hormone (AMH) as only possible marker in the assessment of ovarian function and reserve after hematopoietic stem cell transplantation (HSCT) in prepubertal girls, young females with composed hypogonadism and females receiving hormonal replacement therapy.Bone Marrow Transplant. 2017 Feb;52(2):313-316. doi: 10.1038/bmt.2016.273. Epub 2016 Nov 14. Bone Marrow Transplant. 2017. PMID: 27841859 Clinical Trial. No abstract available.
-
Editorial: Endocrinological sequelae of hematopoietic stem cell transplantation.Front Endocrinol (Lausanne). 2023 Feb 14;14:1151213. doi: 10.3389/fendo.2023.1151213. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36864835 Free PMC article. No abstract available.
References
-
- Kolb HJ, Socié G, Duell T, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late effects working party of the European cooperative group for blood and marrow transplantation and the European late effect project group. Annals of Internal Medicine. 1999;131(10):738–744. - PubMed
-
- Horowitz M. Uses and growth of hematopoetic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, editors. Hematoipoietic Cell Transplantation. 2nd edition. Oxford, UK: Blackwell; 1998. pp. 12–18.
-
- Roziakova L, Mladosievicova B. Endocrine late effects after hematopoietic stem cell transplantation. Oncology Research. 2010;18:607–615. - PubMed
-
- Shalet SM, Didi M, Ogilvy-Stuart AL, Schulga J, Donaldson MDC. Growth and endocrine functiom after bone marrow transplantation. Clinical Endocrinology. 1995;42(4):333–339. - PubMed
-
- Brennan BMD, Shalet SM. Endocrine late effects after bone marrow transplant. British Journal of Haematology. 2002;118(1):58–66. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical